# US 2023/0398241 A1 · Radiolabeled ether dendrimer conjugates for pet imaging and radiotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398241 A1
- Document ID: US20230398241A1
- Status: Published application
- Kind: A1
- Application number: 18/034,551
- Filed: 2021-10-29
- Published: 2023-12-14
- Earliest claimed: 2020-10-30
- Assignees: Ashvattha Therapeutics, Inc.
- Applicants: Ashvattha Therapeutics, Inc.
- Inventors: Jeffrey L. Cleland; Rishi Sharma; Minghao Sun; Santiago Appiani La Rosa
- Web page: https://patentgrep.com/patent/US20230398241A1

## CPC

- A61K 51/065: {conjugates with carriers being macromolecules}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/595: {Polyamides, e.g. nylon (polyamino acids A61K47/62)}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0054: {Macromolecular compounds, i.e. oligomers, polymers, dendrimers}
- A61P 35/00: Antineoplastic agents
- C08G 83/004: {After treatment of dendrimers}
- C08L 101/005: {Dendritic macromolecules}
- A61K 2121/00: Preparations for use in therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

Compositions and methods for detecting, monitoring and imaging inflammatory sites or tumors in a subject have been developed. Compositions of hydroxyl-terminated dendrimers conjugated to radionuclide(s) via ether linkages are provided for both imaging and radiotherapy (tumors). Methods for the non-invasive and specific positron emission tomography (PET) imaging or magnetic resonance imaging (MRI) of dendrimer conjugated to one or more imaging agents in a subject in vivo are also provided. The methods selectively deliver dendrimer conjugated to radionuclides or MRI contrast agents to reactive microglia or reactive immune cells in tumors in the recipient. In some embodiments, the dendrimers conjugated to imaging agents also deliver targeted radiotherapy agents to a tumor, and/or deliver additional diagnostic, therapeutic or prophylactic agents to reactive microglia in the recipient. Methods of making dendrimers conjugated to imaging agents are also described.

## Claims

### Claim 1

A composition comprising hydroxyl-terminated dendrimers conjugated to one or more radionuclides or one or more magnetic resonance imaging (MRI) contrast agents through ether linkages, optionally via one or more linking moieties.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the dendrimers are polyamidoamine (PAMAM) dendrimers, polypropylamine (POPAM) dendrimers, polyethylenimine dendrimers, polylysine dendrimers, polyester dendrimers, iptycene dendrimers, aliphatic poly(ether) dendrimers, or aromatic polyether dendrimers.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the dendrimers are generation 4, generation 5, generation 6, generation 7, or generation 8 PAMAM dendrimers.

### Claim 4 (depends on 1, 2, 3)

The composition of any one of claims 1-3, wherein the one or more radionuclides are selected from the group consisting of 18F, 51Mn, 52Fe, 60Cu, 68Ga 72As, 94mTc, or 110In, 18F, 124I, 125I, 131I, 123I, 77Br, 76Br, 99mTc, 51Cr, 67Ga 68Ga, 47Sc, 51Cr, 167Tm, 141Ce, 111In, 168Yb, 175Yb, 140La, 90Y, 88Y, 153Sm, 166Ho 165Dy, 166Dy, 62Cu, 64Cu, 67Cu, 97Ru, 103Ru, 186Re, 188Re, 203Pb, 211Bi, 212Bi, 213Bi, 214Bi, 105Rh, 109Pd, 117mSn, 149Pm, 161Tb, 177Lu, 225Ac, 198Au, and 199Au, or 89Zr.

### Claim 5 (depends on 1, 2, 3, 4)

The composition of any one of claims 1-4, wherein the one or more radionuclides are 18F, 89Zr, 90Y, or 177Lu.

### Claim 6 (depends on 1, 2, 3)

The composition of any one of claims 1-3, wherein the one or more MRI contrast agents are selected from a group consisting of Gd, Mn, BaSO4, iron oxides, and iron platinum.

### Claim 7 (depends on 1, 2, 3, 6)

The composition of any one of claims 1-3 and 6, wherein the MRI contrast agent is Gd.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The composition of any one of claims 1-7 in an amount effective to selectively accumulate within reactive microglia and/or macrophages at sites of inflammation or in reactive immune cells in tumors.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The composition of any one of claims 1-7, further comprising one or more additional active agents.

### Claim 10

A composition comprising a compound that comprises a dendrimer conjugated to a radionuclide or an MRI contrast agent through an ester, ether, or amide linkage, wherein the dendrimer comprises a high density of surface hydroxyl groups.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the radionuclide or the MRI contrast agent is conjugated to the ester, ether, or amide linkage through a spacer.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the spacer comprises alkyl groups, heteroalkyl groups, or alkylaryl groups.

### Claim 13 (depends on 11, 12)

The composition of claim 11 or 12, wherein the spacer comprises a peptide.

### Claim 14 (depends on 11, 12, 13)

The composition of any one of claims 11-13, wherein the spacer comprises polyethylene glycol.

### Claim 15 (depends on 10, 11, 12, 13, 14)

The composition of any one of claims 10-14, wherein conjugation of the radionuclide or the MRI contrast agent occurs on less than 50% of total available surface functional groups of the dendrimer prior to the conjugation.

### Claim 16 (depends on 10, 11, 12, 13, 14, 15)

The composition of any one of claims 10-15, wherein conjugation of the radionuclide or the MRI contrast agent occurs on less than 5%, less than 10%, less than 20%, less than 30%, or less than 40% of total available surface functional groups of the dendrimer prior to the conjugation.

### Claim 17 (depends on 10, 11, 12, 13, 14, 15, 16)

The composition of any one of claims 10-16, wherein the radionuclide is selected from the group consisting of 18F, 51Mn, 12Fe, 60Cu, 68Ga, 72As, 94mTc, 110In, 18F, 124, 125, 131, 123, 77Br, 76Br, 99mTc, 51Cr, 67Ga, 68Ga, 47Sc, 51Cr, 167Tm, 141Ce, 111In, 168Yb, 175Yb, 140La, 90Y, 88Y, 153Sm, 166Ho, 165Dy, 166Dy, 62Cu, 64Cu, 67Cu, 97Ru, 103Ru, 186Re, 188Re, 203Pb, 211Bi, 212Bi, 213Bi, 214Bi, 105Rh, 109Pd, 117mSn, 149Pm, 161Tb, 177Lu, 225Ac, 198Au, 199Au, and 89Zr.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the radionuclide is 18F, 89Zr, 90Y, or 177Lu.

### Claim 19 (depends on 10, 11, 12, 13, 14, 15, 16)

The composition of any one of claims 10-16, wherein the MRI contrast agent is selected from the group consisting of Gd, Mn, BaSO4, iron oxides, and iron platinum.

### Claim 20 (depends on 19)

The composition of claim 19, wherein the MRI contrast agent is Gd.

### Claim 21 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The composition of any one of claims 10-20, wherein the dendrimer is selected from the group consisting of polyamidoamine (PAMAM) dendrimers, polypropylamine (POPAM) dendrimers, polyethylenimine dendrimers, polylysine dendrimers, polyester dendrimers, iptycene dendrimers, aliphatic poly(ether) dendrimers, and aromatic polyether dendrimers.

### Claim 22 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The composition of any one of claims 10-21, wherein the zeta potential of the compound is between −25 mV and 25 mV.

### Claim 23 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The composition of any one of claims 10-22, wherein the zeta potential of the compound is between −20 mV and 20 mV, between −10 mV and 10 mV, between −10 mV and 5 mV, between −5 mV and 5 mV, or between −2 mV and 2 mV.

### Claim 24 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The composition of any one of claims 10-23, wherein the surface charge of the compound is neutral or near-neutral.

### Claim 25 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 10-24, wherein the dendrimer is conjugated to the radionuclide or the MRI contrast agent through an ether or amide linkage.

### Claim 26 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The composition of any one of claims 10-25, wherein the dendrimer is conjugated to the radionuclide or the MRI contrast agent through an ether linkage.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A pharmaceutical composition comprising the composition of any one of claims 1-26 and a pharmaceutically acceptable excipient.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, formulated for intraperitoneal, intravenous, intrathecal, intratumoral, or oral administration.

### Claim 29

A method for detecting or imaging one or more inflammatory and/or cancer cells in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising a compound that comprises a dendrimer conjugated to a radionuclide or an MRI contrast agent through an ester, ether, or amide linkage, wherein the dendrimer comprises a high density of surface hydroxyl groups.

### Claim 30 (depends on 29)

The method of claim 29, wherein the composition is administered systemically to the subject.

### Claim 31 (depends on 29, 30)

The method of claim 29 or claim 30, wherein the composition is administered via intraperitoneal, intravenous, intrathecal, intratumoral, or oral route.

### Claim 32 (depends on 29, 30, 31)

The method of any one of claims 29-31, wherein the composition is administered in an amount effective to detect, diagnose or monitor one or more inflammatory sites or cancer in the subject.

### Claim 33 (depends on 29, 30, 31, 32)

The method of any one of claims 29-32, wherein the one or more inflammatory sites in the subject are associated with one or more inflammatory diseases, or associated with sepsis or septic shock, or caused by any mechanism of macrophage activation including macrophage activation syndrome.

### Claim 34 (depends on 29, 30, 31, 32)

The method of any one of claims 29-32, wherein the one or more inflammatory sites in the subject are associated with one or more autoimmune diseases or disorders.

### Claim 35 (depends on 34)

The method of claim 34, wherein the one or more autoimmune diseases or disorders are selected from the group consisting of rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, Sjögren syndrome, Myasthenia gravis, Graves disease, Addison disease, Celiac disease, Hashimoto thyroiditis, Pernicious anemia, Guillain-Barre syndrome, Chronic inflammatory demyelinating polyneuropathy, vasculitis, systemic lupus erythematosus (SLE), type 1 diabetes, inflammatory bowel disease, and thyroid diseases.

### Claim 36 (depends on 29, 30, 31, 32)

The method of any one of claims 29-32, wherein the one or more inflammatory sites in the subject include one or more sites of neuroinflammation in the central nervous system.

### Claim 37 (depends on 36)

The method of claim 36, wherein the one or more sites of neuroinflammation in the central nervous system in the subject are associated with Alzheimer's disease.

### Claim 38 (depends on 29, 30, 31, 32)

The method of any one of claims 29-32, wherein the one or more inflammatory sites in the subject are associated with amyotrophic lateral sclerosis (ALS).

### Claim 39 (depends on 29, 30, 31, 32)

The method of any one of claims 29-32, wherein the subject has cancer.

### Claim 40 (depends on 39)

The method of claim 39, wherein the cancer is solid tumor of any type or brain metastases.

### Claim 41 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 29-40, wherein the method further comprises the step of imaging the subject with a molecular imaging device to detect the dendrimers conjugated to one or more radionuclides in the subject, wherein detection of the dendrimers conjugated to one or more radionuclides indicates presence of inflammation or cancer cells.

### Claim 42 (depends on 41)

The method of claim 41, wherein the molecular imaging device comprises a gamma camera for positron emission tomography (PET) scanning or a scanner for magnetic resonance imaging.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method for detecting or imaging one or more inflammatory and/or cancer cells in a subject in need thereof, the method comprising administering to the subject an effective amount of the composition of any one of claims 1-28.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method for treating cancer comprising administering to a subject in need thereof an effective amount of the composition of any one of claims 1-28.

### Claim 45

A method for treating cancer comprising administering to a subject in need thereof an effective amount of a composition comprising a compound that comprises a dendrimer conjugated to a radionuclide or an MRI contrast agent through an ester, ether, or amide linkage, wherein the dendrimer comprises a high density of surface hydroxyl groups.

### Claim 46 (depends on 45)

The method of claim 45, wherein the wherein the composition is administered systemically to the subject.

### Claim 47 (depends on 45, 46)

The method of claim 45 or claim 46, wherein the composition is administered via intraperitoneal, intravenous, intrathecal, intratumoral or oral route.

### Claim 48 (depends on 45, 46, 47)

The method of any one of claims 45-47, wherein the cancer is breast cancer, ovarian cancer, uterine cancer, prostate cancer, testicular germ cell tumor, brain cancer, gastric cancer, esophagus cancer, lung cancer, liver cancer, renal cell cancer and colon cancer.

### Claim 49 (depends on 45, 46, 47, 48)

The method of any of claim 45-48, wherein the effective amount is effective to reduce tumor size.

### Claim 50

A method of making hydroxyl dendrimers covalently conjugated via ether linkages to one or more positron emission tomography (PET) imaging agents or one or more magnetic resonance imaging (MRI) contrast agents, the method comprising etherification of one or more surface groups of the dendrimers prior to conjugation the one or more surface groups of the dendrimers to one or more PET imaging agents, optionally via one or more spacers, and wherein the conjugation is via an ether linkage.

### Claim 51 (depends on 50)

The method of claim 50, wherein the PET imaging agent or the MRI contrast agent comprises a chelator selected from the group consisting of p-SCN-Bn-Deferoxamine, diethylene triamine pent-acetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), diamine dithiols, activated mercaptoacetyl-glycyl-glycyl-glycine (MAG3), and hydrazidonicotinamide (HYNIC).

### Claim 52 (depends on 50, 51)

The method of claim 50 or claim 51, wherein the PET imaging agent comprises radionuclides selected from the group consisting of 64Cu, 89Zr, 90Y, 105R, 111In, 117mSn, 149Pm, 153Sm, 161Tb, 166Tb, 166Dy, 166Ho, 175Yb, 177Lu, 225Ac, 186/188Re, and 199Au.

### Claim 53 (depends on 50, 51)

The method of claim 50 or claim 51, wherein the MRI contrast agent comprises metals selected from the group consisting of Gd, Mn, BaSO4, iron oxides, and iron platinum.

### Claim 54 (depends on 50, 51, 52, 53)

The method of any one of claims 50-53, wherein the dendrimer is further complexed and/or conjugated to one or more therapeutic, prophylactic, and/or diagnostic agents.

### Claim 55

A method for treating a neurodegenerative disorder comprising administering to a subject in need thereof an effective amount of a composition comprising a compound that comprises a dendrimer conjugated to a radionuclide or an MRI contrast agent through an ester, ether, or amide linkage, wherein the dendrimer comprises a high density of surface hydroxyl groups.

### Claim 56 (depends on 55)

The method of claim 55, wherein the neurodegenerative disorder is Alzheimer's disease.

### Claim 57 (depends on 55)

The method of claim 55, wherein the neurodegenerative disorder is ALS.
